IPHA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Innate Pharma

NASDAQ | IPHA

1.93

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$182.07M

Market Cap

-

P/E Ratio

-0.63

EPS

$3.51

52 Week High

$1.41

52 Week Low

HEALTHCARE

Sector

IPHA Chart

Recent Chart
Price Action

IPHA Technicals

Tags:

IPHA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $13M
Total Revenue $13M
Cost Of Revenue $52M
Costof Goods And Services Sold $52M
Operating Income -$52M
Selling General And Administrative $12M
Research And Development $52M
Operating Expenses $64M
Investment Income Net -
Net Interest Income $1.9M
Interest Income $2.4M
Interest Expense $566K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2M
Income Before Tax -$49M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$49M
Comprehensive Income Net Of Tax -
Ebit -$49M
Ebitda -$47M
Net Income -$49M

Revenue & Profitability

Earnings Performance

IPHA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $111M
Total Current Assets $86M
Cash And Cash Equivalents At Carrying Value $66M
Cash And Short Term Investments $66M
Inventory -
Current Net Receivables $1.6M
Total Non Current Assets $25M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $10M
Short Term Investments $14M
Other Current Assets $3.3M
Other Non Current Assets -
Total Liabilities $102M
Total Current Liabilities $33M
Current Accounts Payable $7.9M
Deferred Revenue -
Current Debt -
Short Term Debt $8.7M
Total Non Current Liabilities $69M
Capital Lease Obligations $375K
Long Term Debt $22M
Current Long Term Debt $8.4M
Long Term Debt Noncurrent -
Short Long Term Debt Total $31M
Other Current Liabilities $8.8M
Other Non Current Liabilities $41M
Total Shareholder Equity $8.8M
Treasury Stock -
Retained Earnings -$386M
Common Stock $4.2M
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow -$6.9M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2M
Capital Expenditures $391K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $9.2M
Cashflow From Financing -$6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$49M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $13M
Total Revenue $13M
Cost Of Revenue $52M
Costof Goods And Services Sold $52M
Operating Income -$52M
Selling General And Administrative $12M
Research And Development $52M
Operating Expenses $64M
Investment Income Net -
Net Interest Income $1.9M
Interest Income $2.4M
Interest Expense $566K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2M
Income Before Tax -$49M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$49M
Comprehensive Income Net Of Tax -
Ebit -$49M
Ebitda -$47M
Net Income -$49M

IPHA News

IPHA Profile

Innate Pharma Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Innate Pharma SA is an innovative biotechnology company based in Marseille, France, dedicated to developing advanced therapeutic antibodies for oncology. The firm has established a robust pipeline of proprietary immune-oncology candidates aimed at enhancing treatment outcomes for cancer patients globally. With a strategic focus on monoclonal antibodies and immune-mediated therapies, Innate Pharma is strategically positioned to leverage the burgeoning demand for novel cancer treatments, bolstering its competitive edge and promising growth potential within the biotech sector.

LPTX
+368.57%
$2.05
NVDA
+1.37%
$180.26
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+117.39%
$1.06
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
AMZE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
NIO
-0.72%
$5.46
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
CLSK
+13.79%
$13.45
AXDX
-61.36%
$0.03
AAL
+3.49%
$13.93
TSLA
+1.71%
$426.58
CIFR
+9.30%
$19.15
SOFI
+0.56%
$28.49
INTC
+2.73%
$36.81
BMNR
+9.78%
$31.74
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
MARA
-0.53%
$11.11
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
KVUE
+1.11%
$17.22
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SNDK
-2.47%
$215.04
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
DNN
+3.64%
$2.56
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
AMZN
-0.22%
$229.16
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
BMNU
+18.42%
$7.52
RIG
+6.17%
$4.30
RIVN
+3.98%
$16.18
PW
+18.87%
$0.99
SRM
+53.27%
$10.30
PLTR
+1.35%
$165.77
PFE
-0.03%
$25.71
AAPL
+0.20%
$277.55
HBAN
+0.55%
$16.27
IVP
-20.80%
$0.13
BBD
+3.95%
$3.68
AGNC
+1.53%
$10.56
CETY
-11.20%
$2.06
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
KALA
+42.62%
$0.91
CCL
-1.12%
$25.43
BULL
+6.43%
$9.26
SNAP
-0.39%
$7.61
GOOG
-1.03%
$320.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
RGTI
-1.95%
$25.57
CRWV
+4.20%
$74.29
AVGO
+3.25%
$397.57
WLGS
-5.57%
$0.04
VALE
+2.62%
$12.51
ABEV
0.00%
$2.51
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
PLTD
-1.37%
$7.16
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ORCL
+4.02%
$204.96
UPWK
-0.55%
$19.58
NTNX
-17.74%
$48.34
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
DVLT
-3.61%
$2.13
PCG
+1.78%
$16.01
NOK
+0.33%
$6.08
DEFT
+20.86%
$1.39
CMG
+1.88%
$34.03
AFMD
-34.94%
$0.18
KOS
-1.83%
$1.07
HBI
-0.45%
$6.59
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
BURU
+7.72%
$0.22
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
LPTX
+368.57%
$2.05
NVDA
+1.37%
$180.26
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+117.39%
$1.06
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
AMZE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
NIO
-0.72%
$5.46
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
CLSK
+13.79%
$13.45
AXDX
-61.36%
$0.03
AAL
+3.49%
$13.93
TSLA
+1.71%
$426.58
CIFR
+9.30%
$19.15
SOFI
+0.56%
$28.49
INTC
+2.73%
$36.81
BMNR
+9.78%
$31.74
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
MARA
-0.53%
$11.11
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
KVUE
+1.11%
$17.22
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SNDK
-2.47%
$215.04
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
DNN
+3.64%
$2.56
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
AMZN
-0.22%
$229.16
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
BMNU
+18.42%
$7.52
RIG
+6.17%
$4.30
RIVN
+3.98%
$16.18
PW
+18.87%
$0.99
SRM
+53.27%
$10.30
PLTR
+1.35%
$165.77
PFE
-0.03%
$25.71
AAPL
+0.20%
$277.55
HBAN
+0.55%
$16.27
IVP
-20.80%
$0.13
BBD
+3.95%
$3.68
AGNC
+1.53%
$10.56
CETY
-11.20%
$2.06
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
KALA
+42.62%
$0.91
CCL
-1.12%
$25.43
BULL
+6.43%
$9.26
SNAP
-0.39%
$7.61
GOOG
-1.03%
$320.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
RGTI
-1.95%
$25.57
CRWV
+4.20%
$74.29
AVGO
+3.25%
$397.57
WLGS
-5.57%
$0.04
VALE
+2.62%
$12.51
ABEV
0.00%
$2.51
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
PLTD
-1.37%
$7.16
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ORCL
+4.02%
$204.96
UPWK
-0.55%
$19.58
NTNX
-17.74%
$48.34
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
DVLT
-3.61%
$2.13
PCG
+1.78%
$16.01
NOK
+0.33%
$6.08
DEFT
+20.86%
$1.39
CMG
+1.88%
$34.03
AFMD
-34.94%
$0.18
KOS
-1.83%
$1.07
HBI
-0.45%
$6.59
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
BURU
+7.72%
$0.22
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.